Global Neglected Tropical Diseases Diagnosis Market Size, Share, and COVID-19 Impact Analysis, By Product Types (Conventional Method and Molecular/Modern Method), By Services (Centralized Service and POC Service), By End-Users (Clinical Labs, Hospitals/Clinics, Home Healthcare, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Neglected Tropical Diseases Diagnosis Market Insights Forecasts to 2035

• The Global Neglected Tropical Diseases Diagnosis Market Size Was Estimated at USD 6.78 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.1% from 2025 to 2035
• The Worldwide Neglected Tropical Diseases Diagnosis Market Size is Expected to Reach USD 13.01 Billion by 2035
• North America is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, the global neglected tropical diseases diagnosis market size was worth around USD 6.78 billion in 2024 and is predicted to grow to around USD 13.01 billion by 2035 with a compound annual growth rate (CAGR) of 6.1% from 2025 to 2035. The market for neglected tropical disease (NTD) diagnosis is expanding with increasing disease burden, public health programs, and technological advancements. Greater emphasis on early detection, investments in global health, and creation of innovative, low-cost, and portable diagnostic devices are fueling market growth globally.

Market Overview

The neglected tropical diseases (NTDs) diagnosis market refers to various diagnostic products, assays, and services that are aimed at identifying, monitoring, and controlling infections by diseases such as leishmaniasis, Chagas disease, lymphatic filariasis, onchocerciasis, and schistosomiasis. These diagnoses are important for early detection, disease surveillance, and informing effective treatment in NTD-endemic areas, mainly in Africa, Asia, and Latin America. Primary drivers of this expansion are the relentlessly high disease burden, which affects more than 1.5 billion individuals worldwide, combined with rising global health investment, government and WHO-sponsored programs, and improved molecular and point-of-care diagnosis technologies. Technological adoption, such as AI-driven microscopy and multiplex testing, is improving diagnostic precision and scalability in low-resource environments. Additionally, increased partnerships between governments, NGOs, and international health organizations are promoting market growth through investment in surveillance networks and diagnostic equipment.

Emerging prospects are in low-cost, quick, and portable diagnostic kits, especially designed for remote communities and regional markets such as sub-Saharan Africa and Southeast Asia, where diagnostic penetration is low but demand for trusted, point-of-care solutions is growing. Industry giants such as Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., and Bio-Rad Laboratories are working toward driving innovation and access via cost-effective and field-capable diagnostic platforms. On World Neglected Tropical Diseases (NTDs) Day 2025, marked on January 30, the WHO called for governments, leaders, and communities to unite. Act. Eliminate. NTDs through ambitious, long-term investments. Emphasizing 1.5 billion infected individuals, WHO urged greater commitment, financing, and coordination to provide treatment, interrupt transmission, address disabilities, and break the cycle of disease and poverty.

Report Coverage

This research report categorizes the neglected tropical diseases diagnosis market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the neglected tropical diseases diagnosis market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the neglected tropical diseases diagnosis market. 

Driving Factors

The neglected tropical diseases (NTDs) diagnostic market is spurred by a number of driving factors, which are the widespread global disease burden of more than 1.5 billion individuals, most of whom are in low- and middle-income countries. Increasing government and WHO initiatives to end NTDs are fueling demand for correct and affordable diagnostics. Improved molecular, rapid, and point-of-care testing technologies support earlier identification and surveillance. Increased public health expenditure, intersectoral collaborations, and artificial intelligence integration and digital tools augment market growth further. Also, expanded awareness, enhanced healthcare infrastructure, and investment in low-cost diagnostic solutions in endemic nations continue to drive the market further.

Restraining Factors

The market for the diagnosis of neglected tropical diseases (NTDs) is hindered by limited healthcare infrastructure in endemic areas, costs of sophisticated diagnostic technology, and funding for research and development. Lack of skilled personnel, poor disease surveillance, and low awareness within populations also limit universal coverage and access to diagnostic solutions.

Market Segmentation

The neglected tropical diseases diagnosis market share is classified into product type, services, and end-users.  

• The molecular/modern method segment dominated the market in 2024, approximately 65% and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the neglected tropical diseases diagnosis market is divided into conventional method and molecular/modern method. Among these, the molecular/modern method segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The molecular/modern method segment led the market due to the growing use of advanced diagnostic technologies, including PCR, next-generation sequencing, and in situ hybridization. The factor driving this growth is the increasing demand for early disease detection, personalized medicine, and precise genetic and infectious disease testing. Sustained innovations, increasing applications in oncology and infectious diseases, and heightened awareness among healthcare providers further contribute to its high CAGR in the forecast period. Point-of-care testing and multiplex assay advancements are also predicted to drive market growth.

Regional Segment Analysis of the Neglected Tropical Diseases Diagnosis Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Asia Pacific is anticipated to hold the largest share of the neglected tropical diseases diagnosis market over the predicted timeframe.

Asia Pacific is anticipated to hold the largest share of the neglected tropical diseases diagnosis market over the predicted timeframe. Asia Pacific is expected to account for the largest market share of the neglected tropical diseases (NTD) diagnosis market during the forecast period, owing to a high rate of incidence of dengue, lymphatic filariasis, schistosomiasis, and leishmaniasis in nations such as India, Indonesia, and Bangladesh. It is spurred by rising government support, improved healthcare infrastructure, public awareness, and growing diagnostic capacity. India is putting significant capital into early detection initiatives and advanced diagnostic equipment, whereas Indonesia and Bangladesh prioritize mass screening and mass campaigns at the population level, thus collectively driving market growth.

North America is expected to grow at a rapid CAGR in the neglected tropical diseases diagnosis market during the forecast period. North America is rapidly growing in the market for the diagnosis of neglected tropical diseases over the forecast period, led mainly by the United States. The growth is being driven by the sophisticated healthcare infrastructure, enhanced research and development spending, and the implementation of modern diagnostic technology for early detection and surveillance of NTDs. In addition, growing awareness levels among healthcare practitioners, efforts by the government for disease surveillance, and public-private partnerships to create quick, reliable diagnostic products are driving the growth of the market in the region greatly.

Europe's diagnosis market for neglected tropical diseases (NTDs) is increasing modestly, with the United Kingdom and Germany spearheading this trend. Growth is informed by rising funds for research, developed laboratory facilities, and the implementation of newer diagnostic technologies. Joint initiatives by governments, NGOs, and the private sector to introduce reliable screening tools, coupled with growing awareness of imported cases of NTD through travel and migration, are drivers of market growth in the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the neglected tropical diseases diagnosis market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Coris BioConcept
• Oscar Medicare Pvt Ltd.
• ZeptoMetrix, LLC
• bioMerieux SA
• InBios International, Inc.
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group PLC
• DiaSys Diagnostic Systems GmbH
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the neglected tropical diseases diagnosis market based on the below-mentioned segments: 

Global Neglected Tropical Diseases Diagnosis Market, By Product Type

• Conventional Method
• Molecular/Modern Method

Global Neglected Tropical Diseases Diagnosis Market, By Services

• Centralized Service
• POC Service

Global Neglected Tropical Diseases Diagnosis Market, By End-users

• Clinical Labs
• Hospitals/Clinics
• Home Healthcare
• Others

Global Neglected Tropical Diseases Diagnosis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa